Dr. Sarhan Alshammari
ABO blood group incompatibility occurs in 15-20% of all pregnancies and 10% of those develop hemolytic disease. Transcutaneous bilirubin screening use is increasing but still not widespread To compare neonatal outcomes of DCT positive and DCT negative infants born to blood group O positive mothers To evaluate the effect of neonatal blood group on the severity of hemolysis and neonatal jaundice due to aternal-fetal ABO incompatibility. To investigate the value of transcutaneous bilirubin measurement and first serum bilirubin in predicting the development of significant hyperbilirubinemia later in the first few days in infants with ABO incompatibility
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 